Our work on better understanding pMHC-TCR interactions led to our development of RAPTR, a method that uses pMHC-displaying lentiviruses to infect only antigen-specific T cells. In addition to developing this approach as an antigen discovery tool, we are working to develop new therapeutic strategies that can specifically reprogram immune cells. We are testing the effectiveness of these therapies in in vivo models of cancer and autoimmunity. We also work to engineer more capable viral vectors to enable the next generation of genetically reprogrammed therapies.